respiratory syncytial virus

Showing 4 posts of 4 posts found.


AstraZeneca scores accelerated approval in US and Europe for respiratory syncytial virus drug

February 5, 2019
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, EMA, FDA, MEDI8897, pharma, respiratory syncytial virus

It’s a double victory for AstraZeneca as the company announced its F monoclonal antibody MEDI8897 has been granted accelerated review …


Regeneron abandons respiratory syncytial virus therapy after late-stage failure

August 15, 2017
Manufacturing and Production, Research and Development RSV, Regeneron, pharma, pharmaceuticals, respiratory syncytial virus

Regeneron has announced that the failure of suptavumab, its experimental treatment for respiratory syncytial virus (RSV), in late-stage trials, the …


UK biotech Pulmocide secures $30m for inhalable lung disease therapies

March 20, 2017
Research and Development, Sales and Marketing pulmocide, pulmonary aspergillosis, respiratory syncytial virus

Pulmocide, a UK biotech run by a former GlaxoSmithKline scientists and based in London, has secured $30.4 million in Series …

AstraZeneca takes $445m hit to halt motavizumab

December 22, 2010
Research and Development AZ, AstraZeneca, MedImmune, motavizumab, respiratory, respiratory syncytial virus

AstraZeneca has withdrawn a US licence application for its biologic respiratory treatment motavizumab in a move that will cost the …

Latest content